Solace
Commercial- Indications
- Eczema
Company intelligence / Profile preview
Resilia Pharmaceuticals is a privately held specialty pharmaceutical company focused on acquiring and commercializing high-value but underpromoted therapeutics in dermatology. Its lead products include Ecoza® (econazole nitrate) topical foam for tinea pedis, Neosalus® Cream and Lotion for various dermatoses including atopic dermatitis and allergic contact dermatitis, Recedo® Topical Gel for scar management, Neocera® Advanced Cream for skin barrier repair, and Solace® Eczema Cream. The company has relaunched several products that had previously been unavailable due to supply chain disruptions. Clinical results are based on prior regulatory approvals rather than new clinical trials.
3 more assets in the full pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Resilia Pharmaceuticals.